CoChat

Effect of anti‐ IL ‐1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo‐controlled trial

Rissanen, A., Howard, C. P., Botha, J., Thuren, T., for the Global Investigators · 2012 · Diabetes, Obesity and Metabolism
Cited by 140

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Aims: Evaluate anti‐interleukin‐1β ( IL ‐1β) antibody, canakinumab, in patients with type 2 diabetes and impaired glucose tolerance ( IGT ) in whom hyperglycaemia may trigger IL ‐1β‐associated inflammation leading to suppressed insulin secretion and β‐cell dysfunction. Methods: This 4‐week, parallel‐group study randomized 190 patients with type 2 diabetes 2 : 1, canakinumab versus placebo, into the following treatment arms: metformin monotherapy, metformin + sulfonylurea, metformin + sulfonylurea + thiazolidinedione or insulin ± metformin. IGT population (n = 54) was randomized 1 : 1, canakinumab versus placebo. Primary efficacy assessment was change from baseline in insulin secretion rate ( ISR ) relative to glucose 0–2 h. Results: Mean changes from baseline to week 4 in ISR relative to glucose at 0–2 h or other time points were not statistically significant for canakinumab versus placebo across groups. ISR (relative to glucose) at 0–0.5 h (first‐phase insulin secretion) numerically favoured canakinumab versus placebo in insulin‐treated patients {difference in mean change from baseline [point estimate ( PE )] 3.81 pmol/min/m 2 /mmol/l; p = 0.0525} and in the IGT group ( PE 3.92 pmol/min/m 2 /mmol/l; p = 0.1729). Mean change from baseline in fasting plasma glucose favoured canakinumab in the type 2 diabetes/metformin group and the IGT group; however, differences were not statistically significant. Mean change from baseline in peak insulin level and insulin AUC 0–4 h were statistically significantly higher in the canakinumab group in IGT patients. Canakinumab was well tolerated and consistent with known safety experience. Conclusions: The trend towards improving ISR relative to glucose 0–0.5 h in patients treated with insulin supports the hypothesis that insulin secretion can be improved by blocking IL ‐1β.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2012.01637.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 140

Metadata

Authors
Rissanen, A., Howard, C. P., Botha, J., Thuren, T., & for the Global Investigators
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2012-07-19
Volume
14
Issue
12
Pages
1088-1096
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2039664878
Cited by
140
References
8
FWCI
12.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.